Introducing the people powering the Histolog Scanner

Meet our team of passionate individuals who are committed to advancing cancer research and improving patient outcomes.

Our Team

  • Olivier Delporte

    CEO

  • Etienne Shaffer

    Etienne Shaffer

    CTO & Co-Founder

  • Bertrand Gimmonpré

    Bertrand Gimmonpré

    CFO

  • Leslie Stephens

    Leslie Stephens

    VP Market Access & U.S. Marketing

  • Vanessa Degano

    Vanessa Degano

    VP Finance & Administration

  • Jozef Tanczos

    Jozef Tanczos

    VP Clinical Affairs

  • Fanny Jeanneret

    Fanny Jeanneret

    Data Scientist

  • Frédéric Schmitt

    Frédéric Schmitt

    Head of Clinical Development

  • Eloi Servouse

    Eloi Servouse

    Sales Manager Direct Countries

  • Sandrine Laverge

    Sandrine Lavergne

    Sales Manager France

  • Makfé Makiadi

    Makfé Makiadi

    Healthcare IT Infrastructure Specialist

  • Diego Joss

    Diego Joss

    Principal Electrical Engineer

  • Aurèle Horisberger

    Aurèle Horisberger

    Product Development Manager

  • Victoire Gorden

    Victoire Gorden

    Senior Product & Education Specialist Manager

  • Andrey Naumenko

    Andrey Naumenko

    Head of Software Engineering

  • Ludovic Bontron

    Ludovic Bontron

    Firmware Engineer

  • Patrice Lompech

    Patrice Lompech

    Distribution Director

  • Marie Suard

    Marie Suard

    Interaction & Creative Designer

  • Lola Hänni

    Lola Hänni

    Product Specialist

  • Pierre-Jean Vardanega

    Pierre-Jean Vardanéga

    Software Architect

  • Tadéo Araujo-Ovsienko

    Tadéo Araujo-Ovsienko

    Mechatronics Engineer

  • Marc Leroy

    Marc Leroy

    Embedded System Engineer

Become a part of the team

Board of Directors

  • Dr. Charles S. Carignan is currently the Executive Chairman of Cairdac, and a Director of Biothea Pharma and Prothea. He is an advisor to several Biotech and MedTech companies. He previously served as the CEO of SoniVie ,Executive Chair and CEO of Rex Bionics, as the President and CEO of BionX Medical Technology (sold to Ottobock), founding President and CEO of NinePoint Medical, Executive Vice President and Chief Medical Officer of Novasys Medical, Inc. (sold to Roper), Chief Medical Officer at Boston Scientific, and Vice President of clinical research and medical affairs at Conceptus (sold to Bayer).

    He received a BA from Yale University and an MD from the College of Physicians and Surgeons, Columbia University. He trained in general surgery at Columbia-Presbyterian Medical Center.

    He has served healthcare worldwide participating on committees of the U.S. Food and Drug Administration, Centers for Medicare Camp; Medicaid Services, the World Health Organization, the United Nations, and the U.S. Agency for International Development.

  • From 1981 until 2013, Fabrizio Landi was co-founder and then part of the Executive Management of Esaote, where he held various positions (up to CEO and General Manager). He is currently a Board Member of Menarini Diagnostics, Firma and Silicon Biosystem (Menarini Group). He was also a board member of several Italian and international corporates, including Bracco US, Banca CR of Florence (part of Banca Intesa Group) and Leonardo-Finmeccanica. Since 2014 he is Chairman of Toscana Life Sciences TLS Foundation in Siena, supporting many biomedical and biopharmaceutical start-ups and no-profit and for-profit pharma and biotech research groups. He holds several positions in various Scientific Committees and is also actively involved in Fondazione R&I, focused on supporting Technology Transfer processes in Italy.

    Graduated with a degree in bioengineering at the Milan Polytechnic, Fabrizio has a long career in the Life Science sector, started with Bayer in 1979.

    In 2015, he co-founded Panakes Partners SGR, an investment company focused on Life Sciences Venture Capital activities: at Panakès, he is currently a Managing Partner of the first Fund, dedicated to Medtech and healthcare IT, investing all over Europe since 2016.

  • Before joining Turenne Capital as Investment Director Healthcare in July 2022, Claire worked for 7 years in the Omnes Capital VC Healthcare team. She began her career in research at the Singapore Institute for Neurotechnology. Claire Poulard holds a master’s degree in Pharmaceutical Management and Biotechnology from ESCP Europe and a master in Bioengineering and Neuroscience Innovation from ESPCI (Ecole Supérieure de Physique et Chimie Industrielle).

  • Olivier is CEO of SamanTree Medical, which has developed and commercializes the Histolog Scanner for fresh tissue analysis during cancer surgery or cancer diagnostics biopsies.

    Prior to SamanTree Medical, Olivier was CEO of Miracor Medical for 7 years, SVP Commercial at PneumRx for 3 years (acquired by BTG in 2015) and VP Commercial at Tryton Medical for 5 years. Olivier started his medtech career in management positions at Guidant and Abbott.

    Olivier is also a Venture Partner with SPRIG Equity, a US Venture Capital fund dedicated to best-in-class teams and medical technologies at growth equity and late-stage venture.

    Olivier is a director of Miracor Medical (coronary sinus occlusion & Left ventricular Assist intervention devices), Endotools Therapeutics (Endoscopic Sleeve Gastroplasty) and Intressa Vascular (aortic dissections).

    Olivier earned a Masters Degree in Business from the UCL, Belgium, and an M.B.A. from the University of Chicago.

  • Henry L. Charlton is senior vice president and chief commercial and marketing officer at Intuitive, leading end-to-end customer engagement globally. Previously he was senior vice president and general manager for the U.S. and E.U. regions at Intuitive. Since joining Intuitive in 2003, he has held leadership positions including: chief commercial officer, senior vice president of U.S. sales; vice president of sales, marketing and training in Europe, the Middle East, India, and Africa (EMEIA) and Latin America, Canada and Australia (LACA); vice president, U.S. key accounts, and a variety of other leadership roles.

    Before joining Intuitive, Charlton was at Tidal Software (acquired by Cisco) serving as vice president of Eastern U.S. Sales. He also worked at Securant Technologies (acquired by RSA Securities), Legato Systems (acquired by EMC), and U.S. Surgical Corporation (acquired by Tyco).

    Charlton earned his BA in history and english from the University of Pittsburgh.

Medical Advisors

Comprising a group of leading medical professionals from a range of specialties, our medical advisors bring a wealth of expertise and experience to the table, ensuring that the Histolog Scanner meets the evolving needs of the healthcare industry.

Prof Lux

Prof. Michael P. Lux, MD MBA

Michael’s scientific work mainly focuses on breast cancer, gynecological oncology, health services research, and health economics.

He graduated as an MD in 2002 and obtained a Master in Management of Public Health Systems in 2009. He has since held various positions, including head of the Clinic for Gynecology and Obstetrics in several clinics in Germany. Since March 2019, he has been head of the Cooperative Breast Center Paderborn and the Gynecological Cancer Center at St. Vincenz.

Aïcha Ben Lakhdar

Aïcha Ben Lakhdar, MD

Aïcha is a specialized Pathologist in breast and ENT pathology. With her expertise in evaluating new imaging technologies designed for pathology in an intraoperative setting, she has led several research projects aimed at improving pathology workflow.

She has worked at prestigious institutes like Gustave Roussy Institute and SCP Bichat medical laboratory in Paris.

Dr. Somford

Diedriek Somford, MD PhD

Rik Somford is a urologist specializing in uro-oncology and minimally invasive urology, particularly prostate and bladder cancer. He is affiliated with the department of Urology at CWZ Nijmegen and actively involved in multidisciplinary cancer patient care. Somford is the chair of the Dutch Uro-Oncology Working Group and completed his PhD thesis on localized prostate cancer. He now focuses on improving outcomes for prostate and bladder cancer patients and is the principal investigator for multiple multicenter trials.